E6 peptide + E7 peptide

Peptide-based vaccines or therapies based on the **E6 and E7 peptides** target the E6 and E7 oncoproteins of high-risk human papillomavirus (HPV), such as HPV16. These oncoproteins contribute to cancer development by inactivating tumor suppressor proteins—E6 promotes degradation of p53, while E7 inactivates retinoblastoma protein (pRB)[1][3]. **E6 peptide + E7 peptide** formulations are designed to generate immune responses (especially T cell–mediated) specific to cells expressing these viral antigens, often as therapeutic cancer vaccines for HPV-associated malignancies such as cervical cancer[1][2]. They are commonly investigated as recombinant proteins, long synthetic peptides, or fused peptide constructs, often with various adjuvants (e.g., flagellin, TLR agonists)[1][2]. The mechanism involves induction of antigen-specific cytotoxic T lymphocytes capable of targeting and killing HPV-infected or tumor cells expressing E6/E7 antigens[1][2]. Various mutated or inactivated forms are used to ensure loss of oncogenic activity while retaining immunogenicity[1].

Other names

HPV E6 peptide + HPV E7 peptideHPV16 E6/E7 peptides